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The enhancement of aminonucleoside nephrosis by the co-admini.
stration of protamine. An experimental model of focal segmental
glomerular sclerosis (FSGS) was developed in rats by the combined
administration of puromycin—aminonucleoside (AMNS) and protamine
sulfate (PS). Male Sprague—Dawley rats, uninephrectomized three
weeks before, received daily injections of subcutaneous AMNS (I
mg/lOO g body wt) and intravenous PS (2 separated doses of 2.5 mg/l00
g body wt) for four days. The series of injections were repeated another
three times at 10 day intervals. The animals were sacrificed on days 24,
52, and 80. They developed nephrotic syndrome and finally renal
failure. The time—course curve of creatinine clearance dropped and
showed significant difference (P < 0.01) from that of each control
group, such as, AMNS alone, PS alone or saline injected. Their
glomeruli showed changes of progressive FSGS. The ultrastructural
studies in the initial stage revealed significant lack of particles of
perfused ruthenium red on the lamina rara externa and marked changes
in epithelial cell cytoplasm. Therefore, it is suggested that the admin-
istration of PS enhances the toxicity of AMNS on the glomerulus and
readily produces progressive FSGS in rats resulting in the end—stage
renal disease.
Focal segmental glomerular sclerosis (FSGS) is a condition in
which some glomeruli develop segmental areas of sclerosis.
Patients with this condition present with a nephrotic syndrome
which is resistant to steroid therapy. There is frequent progres-
sion to end—stage renal disease and recurrence in the trans-
planted kidney.
There have been several attempts to develop experimental
models of FSGS in order to study its pathogenesis and pathol-
ogy. Michael and co-workers [1, 2] induced FSGS in unine-
phrectomized rats by the administration of aminonucleoside of
puromycin (AMNS). The lesions induced in the rat glomeruli
were comparable to that of FSGS in man. However, severe
histological changes, including extensive interstitial fibrosis and
renal dysfunction, were not a feature.
In order to produce a more severe FSGS lesion that progress-
es to end—stage renal disease and which more closely mimics
the disease in humans, protamine sulfate (PS) was evaluated to
determine whether it could potentiate the effect of AMNS. It
has been known for some time that PS has a neutralizing effect
on glomerular polyanion [3—5]. Recent studies suggest that PS
also eliminates cationized immune complexes and thereby can
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ameliorate an immune complex nephritis [6—8]. In this paper we
demonstrate that the effect of AMNS on the epithelial cells and
glomerular polyanion is enhanced by the co-administration of
PS, and produces progressive FSGS in uninephrectomized rats
which results in end—stage renal disease and resembles closely
human FSGS.
Methods
Experimental design
The experimental design is depicted in Figure 1. Forty—two
10 to 12 week old, male Sprague—Dawley (SD) rats were used in
this experiment. A left unilateral nephrectomy through a flank
incision was performed on each rat under ether anesthesia.
Three weeks after the nephrectomy, the rats were randomly
divided into four specific groups (A through D). All the rats
received daily injections for four days: Group A (15 rats)
received AMNS and PS, Group B (II rats) AMNS and saline,
Group C (11 rats) PS alone and Group D (5 rats) saline alone.
AMNS (Sigma Chemical Co., St. Louis, Missouri, USA) was
administered subcutaneously in a dose of 1 mg per 100 g body
weight as a 2% solution in 0.9% sodium chloride, PS (from
salmon testicle, Grade X, Sigma Chemical Co.) was injected
intravenously in two doses (separated by a 4 hour interval) of
2.5 mg per 100 g body weight as a 1% solution in 0.9% sodium
chloride. The drug was administered in a divided dose to avoid
the deleterious effect of the drug on the circulation. Saline
(0.9% sodium chloride) was given intravenously in a dose of 0.5
ml per 100 g body weight.
All rats received further four—day series of injections at
10-day intervals. The dose of AMNS in these series of injec-
tions was reduced to 0.5 mg per 100 g body weight. Five rats in
Group A and three rats in each of Group B and C were
sacrificed on day 24 after the second series of injections and on
day 52 after the fourth series, respectively. Five rats in each
group receiving four series of injections were also sacrificed on
day 80. In addition to the rats in the four groups above, a fifth
group (Group E) of five non-nephrectomized rats was studied.
Group E rats were subjected to the same protocol as Group A
rats and were sacrificed on day 80.
All rats were maintained on standard rat diet pellets contain-
ing 20% of crude protein and 0.12% of sodium (Clark King &
Co., Australia) and had free access to tap water throughout the
course of experiment.
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Fig. 1. Experimental design. Group A and E received aminonucleoside
(AMNS) and Protamine sulfate (PS) in 4-day series of injections; Group
B, aminonucleoside (AMNS) and saline; Group C, protamine sulfate
(PS) alone; Group D, saline alone.
Laboratory studies
Twenty—four—hour urine samples were obtained from all rats
(Groups A to E) in metabolic cages for an initial control period
and then fortnightly during the course of the experiment.
During collection periods the rats were allowed free access to
water but no food. All urines were collected with thymol
crystals and were kept at 4°C. Bibod was obtained from the tail
vein of each rat immediately following urine collection. Serum
samples were separated by centrifuging at 3000 rpm for 15
minutes and stored at —20°C, Urinary protein was measured by
the standard turbidimetric method with sulfosalicylic acid [91.
Determinations of urinary protein and creatinine and of serum
albumin, total cholesterol, urea, and creatinine were carried out
on Centrifichem 400 Centrifugal Analyzer (Union Carbide).
Creatinine clearance was assessed from the results of urinary
and serum creatinine and expressed as mllminlkg body weight.
Data on the rats which were sacrificed on day 80 were
statistically analyzed. The time—course curves were compared,
using a two—way analysis of variance on each parameter (Figs.
2 and 3). Difference between groups or mean values was
considered to be significant when P < 0.05.
Pathology
Light microscopy. Portions of kidney removed at nephrec-
tomy and at sacrifice were fixed in 10% buffered formalin.
Staining procedures were performed by standard techniques in
our laboratory [10]. Paraffin sections were cut at 3 pm and
stained with hematoxylin and eosin, periodic acid—Schiff (PAS)
and Masson's trichrome. All glomeruli in randomly selected,
high power fields were examined for evidence of focal sclerosis.
Histometrical measurements. One hundred and fifty to 200
glomeruli from each specimen were examined. The degree of
sclerosis in each glomerulus was subjectively graded on a scale
of 0 to 4: Grade 0, no change; Grade I, sclerotic area less than
or equal to '/4 of glomerulus or distinct adhesion present
between capillary tuft and Bowman's capsule; Grade 2, sclero-
sis of ¼ to total glomerular area; Grade 3, sclerosis of more
than '/2 the glomerulus but not global; Grade 4, global sclerosis.
An Index of Sclerosis (I.S.) was calculated using the following
formula:
lxN1+2xN2+3xN3+4xN4
N0 + N1 + N2 + N3 + N4
where N is the number of glomeruli in each grade of sclerosis.
5 The interstitial volume was estimated with the point counting
technique modified from the method of Bennett, Walker and
Kincaid—Smith till. Five portions of renal cortex in Masson's
— trichrome staining sections were randomly selected, and pho-
tographs were taken using Agfachrome SOL films with light
microscopy photocamera (Leitz Dialux, magnification x 250).
The micrographs were projected on a screen sized to 24 x 16cm
where 121 (11 x 11) points were squarely plotted at a distance
of 1.5cm, and hence 605 (121 X 5) points were analyzed in each
case. The points of glomeruli and large vessels were excluded
from total points. Relative interstitial volume was expressed as
the percentage of points on interstitium to the total.
In these histometrical measurements, statistical analysis be-
tween groups or subgroups was performed using Student's
t-test.
Immunoperoxdase technique. Portions of kidney were fixed
in periodate—lysine—paraformaldehyde (PLP) for four hours,
washed in phosphate buffered saline containing 7% sucrose
several times and snap frozen. A indirect immunoperoxdase
technique [12] was used for identifying immunoglobulins (Ig)
and C3. Each 6 pm cryostat section was incubated with goat
anti-rat IgG, goat anti-rat 1gM, sheep anti-rat IgA and rabbit
anti-rat C3 (Cappel, diluted 1:160) for 30 minutes, followed by
peroxidase—labelled rabbit anti-goat Ig for IgG or 1gM, peroxi-
dase—labelled anti-sheep Ig for IgA and peroxidase—labelled
swine anti-rabbit Ig for C3 (DAKO, diluted 1:80) for 15 minutes,
respectively. Përoxidase activity was detected by using the
substrate diaminobenzidine for 5 minutes. Sections were coun-
terstained with hematoxylin.
Studies in the initial stage
Eighteen male, 10 to 12 week—old SD rats were randomly
divided into three groups of six rats (Groups A', B', and C').
The animals in each group daily received injections according to
the same protocol of group A, B, and C, respectively. Three
rats were sacrificed on day 4 after three day—injections and
another three on day 7 after 4 day—injections. The animals were
kept in metabolic cages during the experiment. Twenty—four
hour—urine was collected for assessment of urinary protein. At
sacrifice, the animals were anesthetized with ether. The abdom-
inal cavity was exposed by a middle line incision. Right kidney
was removed after the ligature on right renal vessels and ureter,
and prepared for light microscopy. Left kidney was perfused for
15 minutes with ruthenium red (RR) solution and then process-
ed for electron microscopy by the method of Kanwar and
Farquhar [13]. Perfusate was prepared as a 0.2% solution of RR
in Karnovsky's aldehyde solution as described by Luft [141.
Thin sections were cut at 60 nm, mounted on carbon-coated
grids, stained with uranyl acetate and lead citrate, and exam-
ined with JEOL 100C electron microscopy operating at 60kV
(JEOL, Tokyo, Japan).
RR counts. Twenty areas of the GBM were randomly photo-
graphed and printed at a magnification of x78,000. The total
number of RR particles in the lamina rara externa (LRE) were
counted in each photograph and the data expressed as the
number of RR particles/pm of GBM,
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Fig. 2. Urinary total protein (A), serum albumin (B) and serum total
cholesterol (C) versus experimental days for groups of
uni-nephrectomized rat; Group A (•, AMNS + PS), Group B (A,
________________________________________________
AMNS + saline), Group C (0, PS) and Group D (, saline). The
0 10 24 38 52 66 80 time-course curves in each figure show a significant differencebetween Group A and every other group (p < 0.01). The mean values
Time, experimental days and standard error are indicated by points and bars.
Another three non-treated SD rats were prepared for the
RR-perfusion and compared with rats in Groups A' through C'.
Results
There was a gradual increase in the mean body weight of each
group of rats throughout the course of the experiment except in
Group A rats in which there was a fall in mean body weight after
day 52, Group A rats were anemic in the final stages of the
experiment.
Biochemistry
All Group A rats showed marked proteinuria, hypoalbumin-
uria and hypercholesterolemia during the course of the experi-
ment (Figs. 2 A—C). Similar but less marked, findings were
present in Group B rats. Serum creatinine and urea levels were
much higher in Group A rats than in rats of any other group
(Figs. 3A and B). Renal failure was demonstrated by the
decrease of creatinine clearance in group A rats (Fig. 3C). Rats
in Groups C and D showed no abnormality in the biochemical
parameters measured. The time—course curve of Group A in
each parameter is significantly different from that of Group B,
C, and D, respectively. Throughout the course of the experi-
ment, rats in Group E had similar urinary protein, serum
albumin and total cholesterol values as rats in Group A. There
was, however, no rise in serum creatinine and urea and no
decrease in creatinine clearance in non-nephrectomized rats.
The relationship between non-nephrectomized and uninephrec-
tomized groups in each parameter are shown in Table 1.
Pathology
Light microscopic findings in the chronic phase. Glomerular
sclerotic lesions were characterized by adhesions to Bowman's
capsule associated with collapse of capillaries and an increase
in PAS-positive mesangial substance. There was slight swelling
and vacuolization of visceral epithelial cells and mild epithelial
proliferation. These findings were observed in glomeruli of the
rats in Groups A, B, and E focally and segmentally. However,
the changes on the same experimental day were much more
severe in rats of Group A than in rats of Group B or E. The
sclerosis in Group A rats which was already seen but mild on
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Fig. 3. Serum creatinine (A) and urea (B), and creatinine clearance
(C) versus experimental days for groups of uni-nephrectomized rats;
Group A (I, AMNS + PS), Group B (A, AMNS -- saline), Group C(0, PS) and Group D (Li, saline). The values of these parameters
showed a progressive rise (A,B) or fall (C) in Group A. The
0 10 24 36 52 66 time—course curves in each figure are significantly different betweenGroup A and every other group (P < 0.01). The mean values and
Time, experimental days standard error are indicated by points and bars.
Table 1. Comparison of laboratory findings between uninephrectomized and non-nephrectomized rats receiving aminonucleoside and
--
protamine sulfatea
Uninephrectomized rats Group A, Day Non-nephrectomized rats Group E, Day
0 52 800 52 80
Urinary proteinb mg/day
Serum albuminb g/liter
Serum total cholesterol" mmol/liter
Serum creatinine' p.mol/liter
Serum urea mmol/liter
Creatinine clearance mi/mm/kg body wt
1.6
30
2.3
69
7
3.0
0.3
1
0.1
3
1
0.1
574 49
14 0
18.8 0.3
218 29
24 3
1.2 0.2
411
23
7.7
384
70
0.4
70
1
0.9
58
3
0.1
1.9 0.5
32 1
2.1 0.1
68 3
5 0
3.5 0.2
593
15
15.5
64
II
3.3
32
0
0.7
5
I
0.4
459 44
18 1
9.4 1.7
60 2
II 2
3.5 0.1
a Each value was obtained from 5 rats sacrificed on day 80 and is indicated by mean and standard error
b Not significantly different between the groups by analysis of variance
Significantly different between the groups by analysis of variance (P < 0.01)
day 24 showed typical focal segmental pattern with hyaline
deposits on day 52. Focal tubular atrophy, variable interstitial
fibrosis and patchy interstitial, mononuclear cell infiltration
were also present (Fig. 4a). On day 80, most of the glomeruli
showed advanced changes and widespread interstitial lesions
developed (Fig. 4b). The histology was very similar to the
end—stage renal disease in human FGS and other forms of
sclerosing GN. No distinct change was found in the kidneys of
Groups C and D.
Histometrical studies (Table 2). The index of glomerular
694 Saito et a!
Injection
flu nu 1111 JIU
A
400
300
200
100
0-
C
4
B
80
60
40
20
0-
Injection
uu uu uu
I
0 10 24 38 52 66 80
Time, experimental days
Injection
flu
0 10 24 38 52 66 80
Time, experimental days
0
E
0
C(5
(5
a,
U
a,C
C
a,
a,0
0
Enhancement of aminonucleoside nephrosis 695
Fig. 4. Light micrographs of the kidney from rats of Group A on days 52 (a) and 80 (b). (a) Most of glomeruli show segmental or global sclerosis.
Djlatated and atrophied tubulj are seen, but normal tubuli are still present. (b) Glomerular changes are advanced and global sclerosis can be seen.
Tubular atrophy and interstitial fibrosis are prominent. (Periodic acid—Schiff, X 100)
Table 2. Index of scierosis at varying periods in each rat group
Groupsa
Experimental
days of
sacrifice
Numbers
of rats in
group
Index of
sclerosis'
Percent
interstitial
volumeb
Beforec
A 24
52
80
5
5
5
5
0.07 0.02
0.60 0.08
1.83 0.11
2.55 006"
15.2 0.9
19.5 1.0
32.7 2.8
42.9 2.7"
B 24
52
80
3
3
5
0.26 0.03
1.58 0.20
1.65 0.26
17.7 0.3
25.5 0.5
30.8 3.5
C 24
52
80
3
3
5
0.08 0.01
0.05 0
0.11 0.03
12.2 0.8
13.3 1.3
17.9 0.5
D 80 5 0.09 0.01 11.9 0.9
E 80 5 1.28 0.15 23.6 1.7
a Group A, receiving aminonucleoside (AMNS) and protamine sul-
fate (PS); Group B, AMNS and saline: Group C, PS alone; Group D,
saline alone
b Means sa
C Five kidneys randomly obtained from rats at the unilateral nephrec-
tomy 3 weeks before the initial injectiond Significantly different, versus each other group on day 80 (P < 0.01)
sclerosis was much higher in Group A rats than in rats from
Groups B and E. Glomeruli of rats from Groups C and D
showed no significant abnormality when compared with the
glomeruli in the kidneys removed at uninephrectomy three
weeks before the initial injection. The similar results were
obtained on the analysis of percent interstitial volumes. In-
crease of Index of Sclerosis and percent interstitial volume was
revealed throughout the course of the experiment when com-
pared between subgroups in Group A. The latter showed that
nearly a half was occupied by the interstitial area in the
histology of rats in Group A on day 80.
Immunoperoxidase studies. Strongly positive deposits of 1gM
and moderate deposits of C3 were present in sclerotic areas in
glomeruli of Group A rats with advanced lesions (Fig. 5).
Weakly positive deposits of IgG and IgA were seen in a
segmental distribution only in a few glomeruli. There were
Groupsa
A' 7.2 1.4 22.2 0.6" 253.3 45.4 20.1 0.5"
B' 5.4 0.9 24.4 0.4 27.4 1.8 26.0 0.5
C' 6.0 0.4 26.9 0.7 4.7 1.8 27.9 0.7
Non-treated 2.6 0.2 28.7 0.6
similar but less intense deposits of immunoglobulins and C3 in
glomeruli of rats from Groups B and E. Apart from a few
highlights, no significant immunoglobulin or complement depo-
sition was found in glomeruli of Groups C and D rats.
Studies in the initial stage
Urinary protein excretion rose on day 5 and remained high in
Group A' rats (Table 3). The rats in Group B' also showed an
increase in urinary protein, but less marked.
Light microscopy revealed no distinct change in the his-
tologic appearnce at this stage, although expanded Bowman's
spaces and tubular hyaline casts were occasionally seen in the
very proteinuric animals. On electron microscopic observation,
effacement of foot processes was present along GBM in pre-
proteinuric phase of the AMNS-treated rats on day 4 (Fig. 6).
This change was milder in Group B' rats (Fig. 6b) than in Group
A' rats (Fig. 6a). On day 7, the cytoplasm of the epithelial cells
containing many electron dense lysosomes covered the GBM in
the glomeruli of Group A' rats (Fig. 7a), and foot processes
completely disappeared. Capillary lumina were occluded by
hyaline—like electron dense materials. The similar changes were
seen but mild in Group B' rats (Fig. 7b). Smaller numbers of
Table 3. Urinary protein and ruthenium red particles on the lamina
rara externa in the initial stage
Day4 Day7
Urinary
protein"
mg/day
Ruthenium
redc
particles!
pm
Urinary
protein'
mg/day
Ruthenium
red C
particles!
a Group A', receiving aminonucleoside (AMNS) and protamine sul-
fate (PS); Group B', AMNS and saline; Group C', PS aloneb Means SE from 3 rats sacrificed
C Each value was obtained from 60 sections (20 x 3 rats) of the lamina
rara externa and expressed as mean SE
d Significantly different, versus each other group (P < 0.01)
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Fig. 5. The kidney from a rat of Group A on day 80 stained for 1gM (a) and C3 (b) by indirect immunoperoxidase technique. Heavy deposits of
1gM and moderate deposits of C3 are observed in sclerotic area of glomeruli. (x400)
Fig. 6. Low—power electron micrographs of glomeruli from rats in Group A '(AMNS + PS) (a) and in Group B(AMNS + saline) (b) on day 4.
Effacement of foot processes is more marked in Group A', compared to that in Group B', which show very minor changes. Abbreviations are: US,
urinary space; CL, capillary lumen; M, mesangial cell; EN, endothelial cell; EP, epithelial cell. (x 5000)
--
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Fig. 7. Low—power electron micrographs of glomeruli from rats in Group A' (AMNS + PS) (a) and in Group B' (AMNS + saline) (b) on day 7.
A greater degree of epithelial injury is shown in a than in b. In 7 a there is an extensive effacment of foot processes and an area of bare basement
membrane in present on the capillary loop containing a hyaline—like, electron dense lesion (asterisk). Blebs and vacuoles are also present within
epithelial cell cytoplasm. These changes were also present in most of group B animals but were much less in degree (b). Abbreviations are: US,
urinary space; CL, capillary lumen; M, mesangial cell. (x5000)
particles of RR were deposited on LRE in Group A' rats than in
rats of other groups even in the preproteinuric phase (Fig. 8).
The numbers of these particles were significantly different
between Group A' and others on day 4 and 7 respectively
(Table 3). The numbers of deposits in Group B' rats also
decreased but were less marked. There was no significant
difference between Group C' and the non-treated rats.
Discussion
In any animal experimental model of human disease it is
important not only that the induced lesions closely resemble the
lesions in humans, but that the animals live long enough to
study the evolution of the disease, the pathogenesis of the
lesions, and the effects of therapy. Many different approaches
have produced experimental models of FGS, including chemi-
cals [1, 15, 16], aging [17—20], obesity [21], remnant kidneys [22,
23] and protein overloading [24]. However, in these studies the
histological changes were restricted mainly to the glomerulus,
were usually not sufficiently severe to progress to end—stage
renal disease, and thus did not mimic the focal sclerotic lesions
found in human FSGS. Our study clearly shows that the
combined administration of AMNS and PS in low doses is not
lethal to the animals, and is a much more efficient method of
inducing FSGS in rats than the administration of AMNS alone.
The fact that Group A (AMNS + PS) rats had much more
severe sclerotic lesions in their glomeruli than Group B rats
(AMNS alone) indicates that glomerular sclerosis in AMNS
nephrosis is enhanced by PS. Furthermore, this technique
produces an FGS lesion which progresses to end—stage renal
failure. This does not occur when AMNS is given by itself.
Many authors [25—28] have shown that AMNS has a toxic
effect on the glomerular epithelial cell and induces a loss of
charge in the glomerulus which results in proteinuria. More-
over, Velosa et al [2] demonstrated, using colloidal iron stain-
ing, that the glomerular sclerotic lesions in chronic AMNS
nephrosis were preceded by polyanion loss and irreversible
injury to the epithelial cell. In addition it has been demonstrated
that PS neutralizes anionic sites in the glomerulus and caused
reversible epithelial damage [3—5]. Therefore, the rationale
behind this study was to see if PS potentiated the effect AMNS
on the glomerular polyanion producing an FSGS which pro-
gressed to end—stage renal disease.
The neutralizing effect on glomerular anionic sites by PS has
recently been studied in the models of immune complex nephri-
tis, although PS has been assumed to act as an agent for
eliminating cationized immune complexes [6]. The effect of PS
in the early stages of our experimental model was demonstrated
by the ultrastructural findings which showed epithelial lesions
and glomerular polyanion loss. RR was used as the marker to
indicate negative charges in the glomerulus. Although RR
: a. —-.-,-. - •
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Fig. S. Electron micrographs of GBM from rats on day 4 (24-hour after the last administration of drugs) perfused by ruthenium red solution a.
Group A' (AMNS + PS); b, Group B' (AMNS + saline); c, Group C' (PS alone). RR particles on LRE were markedly diminished in Group A'
rats, compared to rats in Groups B' and C'. (x78000)
particles are seen in the LRE, the LRI and the cell coats
covering the epithelium and the endothelium, it is the easiest to
demonstrate the regularity of the particles in the LRE in cross
section [13]. In the present experiment RR deposition of the
LRE was decreased when PS was administered with AMNS in
contrast to that observed by the low dose administration of
AMNS alone. This suggests that the mode of action of PS might
be to enhance the initial toxic effect of AMNS on the epithelial
cell, by accelerating the glomerular polyanion loss and the
subsequent excretion of urinary protein and thus inducing
glomerular sclerosis as Velosa et al [2] proposed.
In order to minimize the toxicity of PS the dosage and the
frequency of the PS-administration was determined from the
direct renal perfusion studies of Vehaskari et [51. Multiple
injections of PS alone neither increased proteinuria nor induced
glomerular sclerosis, and the glomerular polyanion loss was not
demonstrated. This inability of PS alone at this comparatively
low dose to produce glomerular damage has been also demon-
strated by other authors [6, 8]. PS is known to have an adverse
effect on the systemic circulation when intravenously injected
[29—32], and multiple injections of PS in large doses can cause
hemodynamic alterations in the kidney and glomerular lesions.
However, in our model this mechanism probably dOes not play
a role because of the doses involved, its rapid in vivo inactiva-
tion, and because the hemodynamic effect is transient [51.
In our experiments extremely high cholesterolemia was ob-
served. Several authors have reported that PS inhibits lipase
activity [33, 34]. Moorhead et al [35] suggested that loss of
lipoprotein lipase activators caused by increase GBM perme-
ability leads to abnormal lipid metabolism which could affect
mesangial function and have a role in the accumulation of
mesangial matrix. This concept was given further support by
Grond et al [16, 22] who studied uninephrectomized rats,
AMNS nephrosis and adriamycin nephrosis and thought that
mesangial dysfunction might be responsible for the eventual
glomerular sclerosis. Moreover, studies of obese rats showed
that hyperlipidemia was followed by high protein excretion in
urine [361 and eventually progressive glomerular sclerotic le-
sions [21]. Therefore, it may be that the abnormal lipid metab-
olism is enhanced by PS and may be one of the factors
accelerating sclerosis in our FSGS model.
The FSGS induced in unilaterally nephrectomized rats is far
more severe than in non-nephrectomized rats. This is in accord-
ance with other studies which have shown that unilateral
nephrectomy promotes lesions in the remaining kidney. This
effect may be induced by glomerular hyperfiltration postulated
by Brenner and Meyer [371 because the reduction in renal mass
produced by uninephrectomy results in an increase in the blood
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flow, glomerular filtration rate and glomerular capillary pres-
sure in a single nephron.
Spontaneously sclerotic glomerular lesions develop in rats
which are more than six months of age [17—20]. It is believed
that this sclerosis is either due to an inherited genetic abnor-
mality or the result of repeated exposure of the glomeruli to
toxic agents. We have avoided any influence of this spontane-
ous glomerular sclerosis in our experiments by using young rats
and having control groups of the same age.
This experimental model of FSGS with its full spectrum of
readily—induced glomerular and interstitial lesions, which closely
resemble the changes of progressive human FSGS, should
facilitate further study of the pathology and pathogenesis of this
condition and the effect of treatment on its relentless course.
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